209 related articles for article (PubMed ID: 33851364)
21. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
22. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
[TBL] [Abstract][Full Text] [Related]
23. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
24. MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
Rodriguez D; Calmon R; Aliaga ES; Warren D; Warmuth-Metz M; Jones C; Mackay A; Varlet P; Le Deley MC; Hargrave D; Cañete A; Massimino M; Azizi AA; Saran F; Zahlmann G; Garcia J; Vassal G; Grill J; Peet A; Dineen RA; Morgan PS; Jaspan T
Radiology; 2022 Jul; 304(1):174-182. PubMed ID: 35412366
[TBL] [Abstract][Full Text] [Related]
25. Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report.
Sakamoto I; Hirotsu Y; Nakagomi H; Ikegami A; Teramoto K; Omata M
J Obstet Gynaecol Res; 2019 Mar; 45(3):743-747. PubMed ID: 30565790
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
[No Abstract] [Full Text] [Related]
27. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
28. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
[TBL] [Abstract][Full Text] [Related]
30. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
31. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
[TBL] [Abstract][Full Text] [Related]
32. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Kaye SB; Lubinski J; Matulonis U; Ang JE; Gourley C; Karlan BY; Amnon A; Bell-McGuinn KM; Chen LM; Friedlander M; Safra T; Vergote I; Wickens M; Lowe ES; Carmichael J; Kaufman B
J Clin Oncol; 2012 Feb; 30(4):372-9. PubMed ID: 22203755
[TBL] [Abstract][Full Text] [Related]
33. Olaparib, a new hope for ovarian cancer.
Samoon Z; Jabbar AA
Indian J Cancer; 2020; 57(3):346-347. PubMed ID: 32675438
[No Abstract] [Full Text] [Related]
34. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
[TBL] [Abstract][Full Text] [Related]
35. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
36. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
37. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
Chen EX; Jonker DJ; Siu LL; McKeever K; Keller D; Wells J; Hagerman L; Seymour L
Invest New Drugs; 2016 Aug; 34(4):450-7. PubMed ID: 27075016
[TBL] [Abstract][Full Text] [Related]
38. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
[TBL] [Abstract][Full Text] [Related]
39. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
[TBL] [Abstract][Full Text] [Related]
40. Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas.
Raab P; Banan R; Akbarian A; Esmaeilzadeh M; Samii M; Samii A; Bertalanffy H; Lehmann U; Krauss JK; Lanfermann H; Hartmann C; Brüning R
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]